Last reviewed · How we verify
ATL-104
ATL-104 is a glucagon receptor antagonist.
ATL-104 is a glucagon receptor antagonist. Used for Type 2 diabetes.
At a glance
| Generic name | ATL-104 |
|---|---|
| Sponsor | Alizyme |
| Drug class | Glucagon receptor antagonist |
| Target | Glucagon receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
Glucagon receptor antagonists are a class of drugs that block the action of glucagon, a hormone that raises blood glucose levels. By blocking glucagon, ATL-104 is expected to lower blood glucose levels and improve glycemic control in patients with diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Abdominal pain
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ATL-104 CI brief — competitive landscape report
- ATL-104 updates RSS · CI watch RSS
- Alizyme portfolio CI